Results 61 to 70 of about 304,324 (330)

Hydroxychloroquine Associated with Lower Glomerular Filtration Rate Decline in Lupus Nephritis

Arthritis Care &Research, Accepted Article.
Background Hydroxychloroquine (HCQ) protects kidney function in lupus nephritis (LN) by preventing flares, yet some cohort studies show no significant benefit in kidney function with HCQ. Clarifying these conflicting findings by showing early and long‐term benefits of HCQ on kidney function preservation is critical. Therefore, we analyzed data from our
Shivani Garg, Brad Rovin, Brad C. Astor, Tripti Singh, Fauzia Hollnagel, Megan Kuik, Lexie Kolton, Callie Saric, S. Sam Lim, Christie M. Bartels   +9 more
wiley   +1 more source

Systemic lupus erythematosus [PDF]

Clinical Medicine, 2017
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease that is highly heterogeneous in its presentation. This can pose significant challenges for physicians responsible for the diagnosis and treatment of such patients. SLE arises from a combination of genetic, epigenetic and environmental factors.
Natasha Jordan, Maliha F Shaikh, David D'Cruz   +2 more
openaire   +3 more sources

Immunological pathogenesis and treatment of systemic lupus erythematosus

World Journal of Pediatrics, 2019
Background Systemic lupus erythematosis (SLE) is a complex and clinically heterogeneous autoimmune disease. A variety of immunological defects contribute to SLE, including dysregulated innate and adaptive immune response.
Lu Pan, Meiping Lu, Jing-hua Wang, Meng Xu, Sirui Yang   +4 more
semanticscholar   +1 more source

Microphysiological Glomerular Filtration Barriers: Current Insights, Innovations, and Future Applications

Advanced Biology, EarlyView.
The glomerular filtration barrier (GFB) is the first step of blood filtration by the kidneys. The concerning increase of kidney diseases makes the development of new models essential. In this context, microphysiological glomerular filtration barriers focus on closely reproducing the physiological architecture of the in vivo GFB: podocytes, glomerular ...
Manon Miran, Kieu Ngo, David Buob, Hanna Debiec, Pierre Ronco, Guillaume Perry   +5 more
wiley   +1 more source

Systemic Lupus Erythematosus [PDF]

, 1967
E. G. L. Bywaters
  +5 more sources

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

Advanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth, Neal I. Callaghan, Locke Davenport Huyer   +2 more
wiley   +1 more source

Systemic lupus erythematosus with subacute cutaneous manifestation – acute on chronic.

Galicia Clínica, 2018
Systemic Lupus Erythematosus (SLE) presents as a continuum, with some patients demonstrating only cutaneous manifestations, such as Chronic Cutaneous Lupus Erythematosus (CCLE) or other more severe organ manifestations as in SLE.
Juliana Lopes, Isabel Almeida
doaj   +1 more source

Glucocorticoids Alter Bone Microvascular Barrier via MAPK/Connexin43 Mechanisms

Advanced Healthcare Materials, Volume 14, Issue 7, March 14, 2025.
Osteoporosis induced by Glucocorticoids (GCs) is a common complication of long‐term GC use in patients with inflammatory and autoimmune conditions, often leading to an increased fracture risk. A 3D bicellular endo‐osteo microfluidic platform is developed to explore pathogenic mechanisms underlying GCs‐induced osteoporosis, highlighting a novel MAPK ...
Eun‐Jin Lee, Peter Lialios, Micaila Curtis, James Williams IV, Yoontae Kim, Paul Salipante, Steven Hudson, Mandy B. Esch, Moshe Levi, Joanna Kitlinska, Stella Alimperti   +10 more
wiley   +1 more source

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Arthritis & Rheumatism, 2011
OBJECTIVE To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab plus standard therapy compared with placebo plus standard therapy in active systemic lupus erythematosus (SLE).
R. Furie, M. Petri, O. Zamani, R. Cervera, D. Wallace, D. Tegzová, J. Sánchez-Guerrero, A. Schwarting, J. Merrill, W. W. Chatham, W. Stohl, E. Ginzler, D. Hough, Z. Zhong, W. Freimuth, R. V. van Vollenhoven   +15 more
semanticscholar   +1 more source

Development and Validation of Machine Learning‐Based Marker for Early Detection and Prognosis Stratification of Nonalcoholic Fatty Liver Disease

Advanced Science, EarlyView.
This study constructs a stacked multimodal machine learning model for nonalcoholic fattly liver disease (NAFLD) by integrating genetic and clinical features, and synthesize an in‐silico quantitative marker (ISNLD) that enables personalized risk stratification for intrahepatic and extrahepatic outcomes of high‐risk individuals of NAFLD.
Lushan Xiao, Lin Zeng, Jiaren Wang, Chang Hong, Ziyong Zhang, Chengkai Wu, Hao Cui, Yan Li, Ruining Li, Shengxing Liang, Qijie Deng, Wenyuan Li, Xuejing Zou, Pengcheng Ma, Li Liu   +14 more
wiley   +1 more source